Although Australia has taken steps in recent years to harmonise its patent laws with those around the globe,...
Let the applicant beware!
Misrepresentations are not just limited to examples
read more
Home / News / Pearce IP Blog
ALL BLOGS BY
Alex May
Alex is an intellectual property disputes lawyer with twelve years’ experience and a track record of obtaining successful outcomes for clients. He specialises in advising pharmaceutical companies on patent litigation and related matters and has a technical background in genetics.
Alex has represented some of the largest pharmaceutical companies in the world in patent disputes relating to blockbuster antiviral, autoimmunity and chemotherapy medicines.
See Alex's full profile
The one-minute guide to life sciences patent eligibility in the US, Europe and Australia
Pearce IP recently reported on the Full Court of the Federal Court decision in Ariosa Diagnostics, Inc v Sequenom, Inc...
Diagnostic tests that rely on a naturally occurring phenomenon patent eligible in Australia
Diagnostic tests that rely on a naturally occurring phenomenon patent eligible in Australia On 18 June 2021, the Full...
Galvanising your exclusive licence: take-home messages from recent case law
Questions to be answered by the High Court in the Lundbeck Appeal: Part Two
Recent decisions of the Australian Federal Court reinforce the need for exclusive patent licences to include all...
How medicine repurposing could unravel the pharma industry in Australia
TGA seeks consultation on issues relating to the registration of off-label medicines: Part 2
As discussed in Part 1 of this blog series, TGA has invited submissions by 23 March 2021 on its consultation paper...
Exclusive licensees: are you stuck in a “No Standing” zone?
Under Australian law, patent infringement proceedings may be started in the Australian Federal Court only by a...
Supply of essential oil for topical use infringes method of treatment patent claims
Supply of essential oil for topical use infringes method of treatment patent claims Justice Nicholas’ 96-page judgment...
Preliminary discovery not justified by fear of a future product launch
In Pfizer Ireland Pharmaceuticals v Sandoz Pty Ltd [2020] FCA 1648, the Federal Court of Australia declined to order...
MHRA Releases Post-Brexit Biosimilar Guidelines
Next year, the UK will conclude its transition from the EU, with the regulation of all medicines and devices to be...